Supporting carers to manage pain medication in cancer patients at the end of life: A feasibility trial. by Latter, Sue et al.
Latter, Sue; Hopkinson, Jane B; Lowson, Elizabeth; Hughes, Jane A;
Hughes, Jacki; Duke, Sue; Anstey, Sally; Bennett, Michael I; May,
Carl; Smith, Peter; Richardson, Alison (2018) Supporting carers to
manage pain medication in cancer patients at the end of life: A fea-
sibility trial. PALLIATIVE MEDICINE, 32 (1). pp. 246-256. ISSN
0269-2163 DOI: https://doi.org/10.1177/0269216317715197
Downloaded from: http://researchonline.lshtm.ac.uk/4650832/
DOI: 10.1177/0269216317715197
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial
http://creativecommons.org/licenses/by-nc/3.0/
https://doi.org/10.1177/0269216317715197
Palliative Medicine
2018, Vol. 32(1) 246 –256
© The Author(s) 2017
Reprints and permissions: 
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/0269216317715197
journals.sagepub.com/home/pmj
Supporting carers to manage pain 
medication in cancer patients at the  
end of life: A feasibility trial
Sue Latter1, Jane B Hopkinson2, Elizabeth Lowson1,  
Jane A Hughes1, Jacki Hughes2, Sue Duke1, Sally Anstey2,  
Michael I Bennett3, Carl May1, Peter Smith1  
and Alison Richardson1,4
Abstract
Background: Carers of people with advanced cancer play a significant role in managing pain medication, yet they report insufficient 
information and support to do so confidently and competently. There is limited research evidence on the best ways for clinicians to 
help carers with medication management.
Aims: To develop a pain medicines management intervention (Cancer Carers Medicines Management) for cancer patients’ carers 
near the end of life and evaluate feasibility and acceptability to nurses and carers. To test the feasibility of trial research procedures 
and to inform decisions concerning a full-scale randomised controlled trial.
Design: Phase I-II clinical trial. A systematic, evidence-informed participatory method was used to develop CCMM: a nurse-delivered 
structured conversational process. A two-arm, cluster randomised controlled feasibility trial of Cancer Carers Medicines Management 
was conducted, with an embedded qualitative study to evaluate participants’ experiences of Cancer Carers Medicines Management 
and trial procedures.
Setting: Community settings in two study sites.
Participants: Phase I comprises 57 carers, patients and healthcare professionals and Phase II comprises 12 nurses and 15 carers.
Results: A novel intervention was developed. Nurses were recruited and randomised. Carer recruitment to the trial was problematic 
with fewer than predicted eligible participants, and nurses judged a high proportion unsuitable to recruit into the study. Attrition rates 
following recruitment were typical for the study population. Cancer Carers Medicines Management was acceptable to carers and 
nurses who took part, and some benefits were identified.
Conclusion: Cancer Carers Medicines Management is a robustly developed medicines management intervention which merits 
further research to test its effectiveness to improve carers’ management of pain medicines with patients at the end of life. The study 
highlighted aspects of trial design that need to be considered in future research.
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Original Article
What is already known about the topic?
•• Carers play an important role in managing patients’ pain medicines at the end of life.
•• Evidence suggests carers have concerns about pain medicines and lack information and support.
•• Interventions for carers have not been adequately developed or tested for effectiveness.
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Introduction
Many people with advanced cancer experience persistent 
pain1 and are typically prescribed analgesics, including 
opioids. Carers – defined as ‘anyone who cares, unpaid, 
for a friend or family member who due to illness, disabil-
ity, a mental health problem or an addiction cannot cope 
without their support’ (https://carers.org) – often help 
patients to manage medicines, especially near the end of 
life (EoL), and their contribution can be crucial to enabling 
patients to remain at home.2,3 Medication management 
requires knowledge and practical skill and involves carers 
in monitoring and interpreting symptoms, as well as select-
ing, administering and evaluating the effectiveness of 
medicines.4,5 Internationally, research has repeatedly 
shown that carers experience difficulties as a consequence 
of their beliefs about pain and analgesics, particularly 
opioids,6–8 knowledge deficits9 and lack of access to infor-
mation and support.10,11 Most studies conclude that health-
care professionals need to provide carers with more 
information, training and continuing support.4,8,10–12
While reports and small-scale evaluations of carer par-
ticipation in medicines management can be found in the 
literature,13,14 these focus on practice development initia-
tives, and there is a lack of reliable research on effective 
methods of supporting carers with medicines manage-
ment.15 No study has attempted to integrate interventions 
with routine palliative care, the majority of interventions 
lack theoretical underpinning and none were designed with 
input from carers and clinicians. Evaluating complex inter-
ventions in palliative care settings inevitably raises ethical 
and methodological challenges,16 but studies reviewed 
included limited discussion of these and none used qualita-
tive methods to explore participants’ views on the feasibil-
ity and acceptability of interventions or study procedures.
Aims and objectives
The study reported here (author submission checklist 
available online) drew on authors’ previous experience 
of developing nurse-delivered interventions17,18 and fol-
lowed Medical Research Council guidance on complex 
interventions.19 Phase I aimed to develop a novel, theo-
retically based, intervention for carers of patients with 
advanced cancer designed to improve pain medicines 
management (Cancer Carers Medicines Management 
(CCMM)) to be delivered by nurses providing home-
based palliative care. The aim of Phase II was to conduct 
a feasibility study, comprising a randomised controlled 
trial (RCT) and qualitative process evaluation, to test trial 
procedures and assess acceptability and feasibility of 
CCMM to carers and nurses to inform decisions concern-
ing a full-scale RCT. Objectives were to determine rates 
of recruitment and retention, to test acceptability and fea-
sibility of trial procedures, to investigate variability in 
outcome scores, to establish acceptability and feasibility 
of CCMM and to identify factors that promote or inhibit 
its utilisation.
Methods
Phase I: intervention development
CCMM was developed using a multi-method, iterative 
process, with expert input from a purposive sample of 
patients (n = 3), carers (n = 12) and health professionals 
(n = 42: 35 community and specialist palliative care nurses, 
3 doctors and 4 pharmacists) from the study sites, who pro-
vided information on carers’ needs for support with man-
aging medicines (see Online Appendix 1). The study also 
included carers from a wider geographical area, who took 
part in user involvement group consultations (n = 23). 
Interview guides were developed from critical insights 
from the initial literature review and were focused on key 
medicines management issues and possible intervention 
components. Data from all sources were synthesised and 
with reference to a theoretical framework (Lazarus’ theory 
of adaptation,20 underpinned by Ward’s representational 
approach to patient education21 and self-efficacy theory22), 
a prototype intervention was developed. This was refined 
further using participatory methods (nominal group tech-
nique and ethnodrama) with two groups of nurses (n = 16) 
What this paper adds?
•• A description of a complex intervention to support carers in managing medications at the end of life;
•• Preliminary evidence of the intervention is acceptable, feasible and beneficial for patient–carer dyads;
•• Identification of features trial design that could be successfully replicated on a larger scale as well as those that require 
modification.
Implications for practice, theory or policy
•• The feasibility trial has helped illuminate important design issues to be considered in future research.
•• The intervention should be evaluated further to examine its effect on outcomes in carers and patients.
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working in community palliative care. A panel of nurses 
(n = 16) and carers (n = 6) then reviewed the refined CCMM 
materials to confirm relevance to clinical context.
CCMM addresses carers’ beliefs, knowledge and skills 
and promotes self-evaluation of competence. It centres on 
a structured conversational process between nurse and 
carer, which has six components forming the acronym 
CARERS (Table 1).
Phase II: CCMM feasibility study
Trial design. A two-arm, parallel group, randomised con-
trolled feasibility trial of CCMM was conducted at two 
sites, in south Wales (SW) and southern England (SE). 
Nurses were randomly allocated to intervention or control 
(usual care) arms of the study at each site. Clusters were of 
patient–carer dyads on the caseload of each nurse. This 
cluster design was used to minimise risk of contamination. 
The nature of the intervention precluded concealment of 
treatment allocation. Further details can be found in the 
study protocol.23
Setting. In SW, health board–employed district nurses had 
generic caseloads that included patients with palliative care 
needs and in SE, two independent hospice palliative care 
providers employed nurse specialists to work in the commu-
nity. These contrasting models are typical of nurse-delivered 
EoL care in the United Kingdom and were chosen to assess 
feasibility issues associated with each. Nurse volunteers for 
the study were sought at each site: invitations were given 
directly to nurses who had recently participated in EoL care 
training (SW) and issued via nurse managers (SE).
Prior to randomisation, nurses completed the 
Knowledge and Attitudes Survey Regarding Pain24 to 
compare pain management knowledge across the two 
groups of nurses. Each nurse was given a sealed envelope 
containing group allocation, determined independently 
(by P.S.) using simple randomisation and concealed until 
nurses opened the envelopes.
Participants. The study used a consecutive convenience 
sample of patients on the study nurses’ caseloads. Nurses 
screened patients for eligibility (see Table 2) and were 
asked to consider all dyads meeting eligibility criteria as 
potential participants, in combination with clinical judg-
ment about appropriateness of inviting participation.
Intervention delivery. Intervention group nurses received 
one day’s training on CCMM, designed and facilitated by 
specialist palliative care educators (S.A., S.D.). Training 
included preparation for and rehearsal of the CCMM inter-
vention, as well as an overview of the study design and 
processes. To support intervention, delivery nurses were 
provided with a conversational process script, access to an 
online video demonstration and a prompt card. Nurses 
were asked to document use of CCMM components by 
completing a structured reflective record soon after each 
CCMM consultation.
Trial procedures. Study recruitment and data collection 
procedures are summarised in Table 3. Following carer 
completion of baseline questionnaires, nurses in the inter-
vention group delivered CCMM to carers at the next 
appropriate home visit. At subsequent routine contacts, 
Table 1. Components of Cancer Carers Medicines Management (CCMM).
CCMM conversational process CCMM toolkit: Taking charge of cancer pain
Nurse initially works through the steps below in one face-to-face session 
with carer. At subsequent contacts nurse addresses any questions and 
revisits aspects of the conversational process.
Nurse introduces resources and tools as appropriate to meet 
individual needs for information and support identified through 
conversational process. At subsequent contacts, nurse reviews 
use of toolkit resources.
Consent Explain purpose, your role. Consent from patient to 
discuss pain management with carer.
Frequently asked questions about pain medicines: 
information about using morphine in Q&A format
Medicines chart: to be completed jointly by nurse and carer
Record of medicines taken: for carer to chart regular and 
additional pain medication
Pain diary: explanation and suggested simple format diary
What works best for pain? Chart for collating information 
to help assess effectiveness pain management
Anticipating tool: planning how to respond to situations 
that may arise
Stop, look, ask, listen and respond: tool to help 
carer decide what to do when they feel uncertain or 
overwhelmed about managing pain medicines
Important local contact telephone numbers
Details of organisations providing further information and 
support
Assess Explore beliefs and previous experiences of cancer 
pain and pain medicines, assess support and other 
resources available and prioritise knowledge and 
skills needs.
Review Prescribed and non-prescribed medicines. Review 
medicines chart if available or draw one up.
Education Provide coaching for the educational and 
information needs prioritised for this visit.
Review Make plans for review and provide resources, if 
needed.
Support Invite naming of what has been learnt, reinforce 
support available, including who to phone if any 
problems before planned review time.
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nurses could address participants’ questions and reinforce 
the intervention (Table 1).
Outcomes
Feasibility and acceptability. Data were collected on num-
bers of dyads screened, assessed as eligible, recruited and 
retained. Nurses’ and carers’ experiences of research pro-
cedures and CCMM (intervention group) or pain medica-
tion management practices (control group) were explored 
in face-to-face semi-structured qualitative interviews. 
Interview guides were informed by normalisation process 
theory (NPT), a framework for assessing compatibility 
of trial procedures with clinical practice and identifying 
factors that influence perception and utilisation of com-
plex interventions.30 Intervention group nurses’ reflective 
records were used to capture intervention delivery and uti-
lised in conjunction with interview data to assess fidelity 
of intervention delivery.
Carer and patient outcomes. Measures assessed for 
acceptability and responsiveness to CCMM exposure in 
carers were knowledge, beliefs and skills in cancer pain 
medicines management (Family Pain Questionnaire26); 
self-efficacy in pain management (Zeiss Caregiver Prob-
lem-Solving Self-Efficacy27) and strain (Caregiver Strain 
Index28). A secondary outcome was patients’ perceived pain 
(Brief Pain Inventory–Short Form25). Data collection points 
were selected to test sensitivity of measures and to test feasi-
bility of completing a measure at 4 weeks post-intervention 
in people approaching EoL. Carers also self-completed an 
assessment of mood (Profile of Mood State–Short Form29) 
at baseline only. Carers in both intervention and control 
groups were asked to complete measures at baseline, 1 and 
4 weeks and to take part in 1- and 4-week interviews.
Sample size. A target sample size of 30 patient–carer dyads 
per arm was selected to enable estimation of sample size 
for a possible follow-on RCT31 based on the outcome 
measure showing greatest change in response to CCMM. 
Previous research with a similar group of carers suggested 
we should assume a 50% non-participation and attrition 
rate;32 therefore, the plan was to approach up to 120 
patient–carer dyads.
Analysis. Rates of eligibility, recruitment and attrition 
were calculated as percentages. Interviews were audio-
recorded, transcribed verbatim and anonymised. Analysis, 
using the framework approach,33 was led by one researcher 
(E.L. – carer interviews and J.A.H. – nurse interviews) 
with research team members (S.L., J.B.H., A.R. and C.M.) 
reading a sample of transcripts. For the nurse interviews, 
thematic frameworks, generated inductively and informed 
by NPT, were used to organise data. Due to the small sam-
ple size of carers, case reports were constructed; themes 
were synthesised from these into a composite, interpretive 
‘case study’.34
Ethics approval. The study was approved by NRES Com-
mittee South Central Hampshire B (ref. 12/SC/0365, 4 
September 2012). Research governance approval and per-
mission for researcher access were granted by NHS organ-
isations, independent healthcare providers and other 
gatekeeper bodies. All patients, carers and healthcare pro-
fessionals participating in Phase II provided written 
informed consent.
Results
Phase II
Feasibility and acceptability of trial procedures
Recruitment and retention of nurses. The target number 
of 12 nurses took part in the study. Two nurses at each 
site (2 from control group and 2 from intervention group) 
withdrew for reasons unrelated to the research. A total of 
10 nurses took part in post-study interviews.
Nurse pain knowledge and attitudes. Nurses at the two 
study sites had similar baseline pain knowledge and attitudes 
scores: nurse specialists (SE): mean = 29/40, range = 18–35; 
district nurses (SW): mean = 27/40, range = 24–31. Post-
study re-testing showed little change (SE: 30/40, 25–34 and 
SW: 29/40, 26–32).
Randomisation. No difficulties were encountered in ran-
domising nurses. At interview, some nurses said they had 
entered the study with a preference for the intervention 
Table 2. Carer eligibility criteria.
Inclusion criteria Exclusion criteria
Aged 18 years or over Non-English speaking
Supporting a patient with advanced cancer (no longer receiving potentially 
curative treatment) at home
Carers or patients were assessed by their 
nurse to lack capacity to consenta
Supporting a patient who had been prescribed analgesia for cancer-related pain  
Self-reported full or partial responsibility for managing the patient’s medicines  
Agreement from the patient to take part  
a Capacity to consent was judged to be present when the patient and carer could understand the information relevant to participating in the study, 
retain that information, use or weigh that information as part of the process of making the decision and communicate his/her decision.
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group, but all accepted their group allocation. Analysis of 
interviews indicated control group nurses had not become 
aware of intervention details or altered their pain manage-
ment practice. Interviews with carers did not reveal any 
concerns about their nurse’s group allocation.
Eligibility, recruitment and retention of carer partici-
pants. Data collection took place between March and 
September 2014. The flow of participants through the trial 
is shown in Figure 1. Full demographic and clinical data 
were collected on patients and carers (n = 9) who com-
pleted the trial (see Table 4).
Nurses received fewer than predicted referrals during the 
study period and assessed a high proportion of them as 
ineligible (78%) (reasons included non-cancer, no pain, no 
carer and other perceived physical or psychological demands 
on them). Initial estimates of referrals may have been inac-
curate, but during the trial, contextual factors (i.e. reorgani-
sation of nursing teams, staff turnover and sickness absence) 
and changes in clinical practice (e.g. patients being referred 
very close to EoL to district nurses) impacted unpredictably 
on the number of eligible patients. On average, nurses 
approached three dyads each during the 6-month data col-
lection period (median = 3 and range = 0–8), obtained verbal 
consent from 1.75 dyads (median = 1.5 and range = 0–6) and 
recruited 1.25 dyads (median = 1 and range = 0–3).
Analysis of nurse interviews distinguished various 
obstacles to recruitment (Table 5). These included reports 
Figure 1. CONSORT flow diagram for the CCMM study.
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of ‘protecting’ patients and carers from perceived addi-
tional burden and distress that might be raised by demands 
of the research and nurses’ not approaching some patients/
carers to avoid their own disappointment caused by dyads 
declining participation.
The demographic and clinical profiles of participating 
dyads suggest that nurses were selective: carers were rela-
tively young (mean age = 56 and range = 37–68) and the 
majority had university level education. Average scores for 
mood disturbance (POMS-SF; median = 25 and interquar-
tile range (IQR) = 13–36) and carer strain (Carer Strain 
Index (CSI); median = 4 (out of 12)) were low. Most dyads 
had medicines management routines in place, and carers 
reported experience of medicines management in their 
personal or occupational background.
Data collection. Feasibility of self-completed ques-
tionnaires for measuring carer outcomes was confirmed: 
100% of POMS questionnaires were returned at baseline 
and approximately 90% of all other questionnaires were 
returned at each time point, with relatively few missed 
items or obviously incorrect responses.
Nurses completed 85% of patient pain assessments with 
the patient using Brief Pain Inventory–Short Form 
(BPI-SF). At interview, some highlighted difficulties, par-
ticularly for patients who were very ill or reluctant to talk 
about their illness. Several nurses described the assessment 
as ‘cumbersome’ and ‘quite onerous’ and reported adapting 
the questionnaire. These findings raise questions about the 
feasibility of nurse-administered pain assessment using 
BPI-SF.
Three nurses completed reflective records for four of 
the six visits at which CCMM was initially delivered. The 
contemporaneous documents supplemented accounts of 
intervention delivery given in interviews. However, self-
report provided insufficient data to reliably assess inter-
vention fidelity; it would have been preferable to observe 
or audio-record a sample of nurse visits at which CCMM 
was used.
Acceptability and utilisation of CCMM
Nurses’ use of CCMM. Findings from intervention group 
nurse interviews (n = 6) were mapped against NPT catego-
ries of implementation work (sense-making, participation, 
action and monitoring) to assess CCMM’s implementation 
potential and identify how it might be optimized.23 Full 
details are provided in Online Appendix 2 and summarised 
below.
CCMM made clinical sense to nurses, who recognised 
the challenges faced by carers managing analgesia at the 
EoL and saw potential benefits in improving education and 
support. However, nurses did not find CCMM sufficiently 
new or distinctive, and said they were already using some 
components of the intervention, although this claim was 
not supported by control group nurses’ descriptions of rou-
tine practice. Nurses tended to equate CCMM with provid-
ing written information and resources, rather than seeing it 
as a conversational and educational process.
Positive experiences of CCMM training helped nurse 
engagement. However, due to low recruitment, each nurse 
used CCMM with only one or two dyads and not all nurses 
became confident delivering it. Nurses gave examples of 
CCMM benefiting carers, although some nurses were con-
cerned that focusing specifically on pain could potentially 
increase patient/carer anxiety about this issue. At the end 
of the trial, CCMM was compared favourably with current 
practice because it offered a more systematic and compre-
hensive approach to supporting carer management of pain 
medicines. Nurses particularly valued the toolkit resources, 
that is, information about opioids and simple charts for 
documenting pain and medication, because they were of 
immediate practical value to carers.
Nurses found CCMM generally compatible with exist-
ing work practices: it was easy and quick to deliver and 
adaptable to family circumstances, concerns raised by car-
ers and the time available during a visit. However, CCMM 
resources were not always used selectively as had been 
intended: nurses tended to give the complete toolkit to car-
ers. Nurses found CCMM’s specific focus on pain medi-
cines difficult to reconcile with their holistic approach to 
managing a range of EoL symptoms and associated medi-
cines. They also suggested that expanding the intervention 
Table 4. Carer and patient demographic and clinical data.
Intervention 
group
Control 
group
Female (carer) 5 (100%) 3 (75%)
Female (patient) 2 (40%) 1 (25%)
Age (mean)
 Carer 54.6 years 57.5 years
 Patient 72 years 69.5 years
Carer ethnicity
 White British 5 (100%) 4 (100%)
Carer educational qualifications
 No qualifications 3 (60%) 1 (25%)
  Qualifications below University 
level
– –
 Qualifications at University level 2 (40%) 3 (75%)
Carer relationship to patient
 Spouse 1 (20%) 4 (100%)
 Daughter 3 (60%) –
 Sister 1 (20%) –
Cancer site
 Metastatic bone 4 (80%)  
 Oesophagus 1 (20%)  
 Spinal cord 1 (25%)
 Lung and liver 1 (25%)
 Bowel 1 (25%)
 Missing 1 (25%)
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to include life-limiting conditions other than cancer would 
increase its applicability and enhance its compatibility 
with palliative care nursing practice. Nurses also favoured 
introducing CCMM earlier in the course of a patient’s ill-
ness, which was felt more appropriate and of greater ben-
efit to carers.
Carer experience of CCMM. Nine family carers were 
interviewed (five intervention and four control; 17 inter-
views). Although carers had some difficulty in isolat-
ing CCMM from their overall experience of caring for 
a patient at the EoL, most commented on the value of 
CCMM resources in the toolkit, particularly for informa-
tion, reassurance and supporting problem-solving. Within 
the data, we identified some positive changes in medicines 
management, such as increased acceptance of the need 
for opiates, knowledge being reinforced or enhanced and 
behavioural change, for example, responding more readily 
Table 5. Factors influencing recruitment of study participants.
Obstacles Illustrative quotes from nurse interviews (n = 10)a
Contextual factors: organisational change, team 
staffing levels, nurse workloads and variable flow of 
palliative care referrals (district nurses)
‘I then had a full caseload so I wasn’t taking on any new patients for quite 
a long time. […] We’ve had the consultants doing first visits and I would 
follow on afterwards because we’ve been so short staffed’. (N02cSE)
A low proportion of palliative care referrals meeting 
study eligibility criteria.
‘when we had a new palliative patient I was keen to get there and then 
they weren’t suitable. […] some of the palliative patients don’t have pain 
[…] If they had a care agency or they didn’t have a regular carer […] quite 
often they’d manage [their medication] themselves, if they had the capacity 
to consent’. (N14iSW)
Nurses’ unfamiliarity with research recruitment, 
coupled with infrequent opportunities to use study 
procedures: nurses emphasised the need for practice 
to achieve a fluent approach they felt confident about.
‘I found [practising the recruitment procedure] quite helpful because 
it is difficult when you’re adding something. […] it was nice to be able 
to practice how you might approach it. And I think I felt much more 
comfortable doing that’. (N01iSE)
Incompatibility of recruitment procedures with 
nursing practice at a first visit: recruitment could be 
impeded by patient fatigue, time constraints on the 
nurse and difficulty assessing capacity to consent.
‘to start with I found [introducing the study] difficult because there were 
so many other things that you had to talk about [at the first visit] and I 
tended to leave it to the end because I could then concentrate solely on 
that. But [pause] by that stage they’d kind of switched off. They’d had 
enough. […] It was all too much to take on board’. (N11iSW)
Nurses ‘protecting’ patients and carers from 
additional burden or distress: some nurses did not 
approach eligible dyads they judged unable to cope 
with research demands.
‘I felt quite uncomfortable [introducing the study] sometimes, because I 
knew it was going to add to the burden of everything else that they were 
doing’. (N01iSE)
‘There was just so much anxiety and so many other problems […] It was 
almost like [introducing the study] would have been too much and the 
thing that broke everything and it just fell apart’. (N04cSE)
Nurses’ avoidance of difficulty and disappointment: 
some nurses described pre-judging patients’ and 
carers’ willingness to participate, to avoid invitations 
being declined, which they found discouraging.
‘I always went with the idea this is a new palliative patient that could be 
a candidate for the study. […] [in one case] you could see it was all a bit 
too much for them so it didn’t seem appropriate. And another person was 
extremely deaf and his daughter didn’t really engage […] So I went in with 
an open mind but on certain cases […] if I felt it would be a very difficult 
recruit I thought, well don’t even initiate it, you know’. (N13iSW)
Recruiting fewer dyads than anticipated affected 
nurses’ engagement and the priority they gave to the 
study
‘when we were doing the training it’s just right there. And then it slips 
to tenth place. And if you haven’t recruited, it’s twentieth place because 
you’re doing this, this and this’. (N06iSE)
Facilitators
Nurses’ initial enthusiasm for participating in research 
and agreement with the purpose of the study
‘I think anything that’s going to improve patient symptoms and also the 
care, the support they get from the carers. I think often carers can be a 
forgotten group and they take a lot of responsibility. If there were tools 
that were going to be helpful that’s a win-win situation’. (N03iSE)
Preparation and continuing support provided by the 
research team
‘I think that was good the way we had instant access to you [researchers]. 
[…] you were OK with us phoning at any time. […] particularly when we 
weren’t that familiar with it. […] and you followed us up regularly and you 
were accessible when we needed you. You were there which was nice’. 
(N01iSE)
[…]: text of transcript has been edited for clarity and brevity.
a Quotes are tagged with a composite code that provides unique nurse study ID (first letter followed by two digits), group allocation (i or c, interven-
tion or control) and study site (south England (SE) or south Wales (SW)).
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to patients’ requests for pain relief and improved systems 
in place for giving and recording medicines. There were 
no reports from carers of CCMM increasing the burden 
of caring or otherwise causing harm or distress (Online 
Appendix 3).
Discussion
Phase I enabled the development of a novel, theory-based 
intervention to support carer management of pain medi-
cines, grounded in current EoL care context, as well as 
research and expert evidence. Although caution in inter-
pretation is required due to the small sample, data indicate 
that the intervention was acceptable to nurses and carers, 
was feasible to deliver in practice, and showed some 
benefits.
Qualitative data from carers were suggestive of poten-
tial benefits for their knowledge, beliefs and behaviours 
related to management of pain medicines. However, some 
nurses reported that CCMM could potentially raise patient 
and carer anxiety through its focus on pain. Due to prob-
lems with recruiting our target sample size, we were unable 
to conduct a reliable analysis of variability in outcome 
scores and therefore select a primary outcome or determine 
sample size for future research. All carer outcome measures 
proved feasible to complete, with little missing data, sug-
gesting suitability for future research, but nurses’ reported 
difficulties measuring patient pain using the Brief Pain 
Inventory (BPI) and alternative methods may be required.
The need for CCMM made sense to nurses and was 
largely compatible with their clinical practice and helped 
to systematise it. However, nurses highlighted challenges 
caused by focusing solely on pain, and in future research, 
consideration should be given to expanding CCMM to 
include medicines used to manage other symptoms at EoL, 
making it more compatible with nurses’ holistic focus. 
Nurses had some difficulty distinguishing CCMM from 
routine practice and tended to distribute the written 
resources indiscriminately to carers rather than engaging 
them in a conversational process. Nurses needed more 
opportunity to reflect on current practice and practise 
CCMM before the trial proper to be confident about and 
competent in using CCMM.
Some aspects of study design proved feasible and could 
be replicated in a larger scale trial: both specialist palliative 
care nurses and community nurses were recruited, and ran-
domisation was acceptable; in keeping with findings from 
other studies,35 using a cluster design with nurses ran-
domised within-site did not prove problematic with respect 
to control group contamination. The study also reinforced 
the usefulness of qualitative methods of evaluation in stud-
ying experiences of acceptability and feasibility.
The main obstacle to feasibility was carer recruitment, 
partly attributable to fewer than expected eligible partici-
pants. Rather than simply accepting managers’ estimates 
of palliative care referrals, we could have carried out a 
rapid audit to check viability. Recruitment problems were 
also attributable to low proportions of eligible carers 
invited by nurses. Our findings are suggestive of a high 
degree of gate-keeping by nurses, similar to recruitment 
problems described in other recent trials.36,37
Organisational issues and fundamental conflicts 
between clinical and research roles appeared to exist. 
Schildmann and Higginson16 recommend screening for 
eligibility is done by research staff, while Stone et al.38 
argue for careful monitoring of the recruitment process, so 
that reasons for low recruitment by clinical staff can be 
identified and managed. Research staff access to patients 
and carers may also be facilitated by recruiting at hospital 
discharge or through out-patient clinics.
Gatekeeping may also result in selection bias and thus a 
risk of inequity in patient and carer access to an interven-
tion. The small sample of dyads recruited to this study did 
not appear to be typical – they were younger and function-
ing well – a theme in other studies.39 In a pragmatic study, 
it is perhaps impossible to completely eliminate risks of 
selection bias, but checks can be introduced, so that biases 
can be identified. We did not collect data on all eligible 
participants, so could not systematically compare the char-
acteristics of those nurses invited and those they did not. 
This should be part of the protocol of future studies in 
which healthcare professionals recruit participants, if eth-
ics committees are prepared to allow this.40
Finally, it may be important to reconsider the recruit-
ment of dyads and focus on carer outcomes alone, as 
CCMM is a complex psychoeducational intervention for 
carers. Parallel consent of both patient and carer made the 
recruitment process complex with exclusion of some car-
ers because the patient did not have capacity to consent. 
Others have also concluded that recruiting both patients 
and carers extends the recruitment phase.41
Conclusion
CCMM is a robustly developed, novel medicines manage-
ment intervention which merits further evaluation to test 
effectiveness at improving carers’ management of pain 
medicines with patients at EoL. This feasibility trial has 
helped illuminate important design issues that would need 
to be incorporated into a definitive trial.
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